Contact: Jennifer Cook Williams
Investor Relations
360-668-3701

IMMUNOCELLULAR THERAPEUTICS APPOINTS DRS. PETER BROOKS AND SHERIE MORRISON TO SCIENTIFIC ADVISORY BOARD

LOS ANGELES, CA – October 14, 2008 – ImmunoCellular Therapeutics, Ltd. (OTC: IMUC.OB) (IMUC), a biotechnology company, announced today that it has appointed Peter Brooks, Ph.D. and Sherie Morrison, Ph.D. to the company's Scientific Advisory Board. Dr. Brooks of the Maine Medical Center Research Institute brings extensive expertise in the monoclonal antibody area, having participated in the research and development of multiple anti-cancer compounds. Dr. Morrison of the University of California, Los Angeles is a world renowned antibody researcher, having published hundreds of papers and patents and who has also acted as keynote speaker at a number of antibody conferences.

Dr. Peter Brooks recently joined the Maine Medical Center Research Institute, where he is focused on studying mechanisms that regulate angiogenesis, tumor growth and metastasis. Prior to joining that Institute, Dr. Brooks served as associate professor and director of Angiogenesis and Radiation Research at New York University (NYU) School of Medicine. Before his association with NYU, Dr. Brooks was an assistant professor at the USC School of Medicine, during which time he also co-founded Cell Matrix Incorporated, a biotechnology company focused on anti-angiogenic drugs targeting cryptic ECM epitopes. Dr. Brooks' studies have led to a recent clinical trial to evaluate the effects of D93, a humanized antibody directed to a cryptic collagen epitope for the treatment of malignant tumors. Dr. Brooks obtained his Ph.D. in Cell and Developmental Biology from the State University of New York at Stony Brook.

Dr. Sherie Morrison is a distinguished professor of Microbiology, Immunology and Molecular Genetics at the University of California, Los Angeles. Dr. Morrison joined the faculty of UCLA in 1988 and acted as department chair for 10 years. Prior to that, Dr. Morrison served as professor in the Department of Microbiology at Columbia University College of Physicians and Surgeons, which followed various post-doctoral fellowships at Columbia University, University of California, Berkeley and Albert Einstein College of Medicine. Her long-time research interest has been the functional properties of antibodies and novel antibody-related proteins, and she is well published in this area. Dr. Morrison holds Ph.D. and B.A. degrees from Stanford University.

"We are extremely pleased to have Drs. Morrison and Brooks join our Scientific Advisory Board. While our cancer vaccine and cancer stem cell technologies are either in or approaching the clinical stage, we are equally excited about the potential of our preclinical-stage monoclonal antibody therapies, and we believe that the extensive experience that Sherie and Peter bring in this area can assist us in advancing our antibody therapies to the clinic more rapidly," stated Manish Singh, Ph.D., president and chief executive officer of IMUC. "We have observed promising preclinical data in our monoclonal antibody program demonstrating high specificity of these antibodies to target certain cancers, and we are also developing a diagnostic test to potentially screen patients with certain tumor markers who are most likely to benefit from our therapies."

About ImmunoCellular Therapeutics, Ltd.

IMUC is a Los Angeles-based clinical-stage company that is developing immune based therapies for the treatment of brain and other cancers. IMUC's lead product candidate—a dendritic cell-based vaccine for treating brain tumors—is currently being evaluated in a Phase I clinical trial. Additionally, the company is developing a therapeutic vaccine targeting cancer stem cells for multiple cancer indications and is also evaluating its platform technology for monoclonal antibody discovery using differential immunization for diagnosing and treating multiple types of cancer. To learn more about IMUC, please visit www.imuc.com.

Forward-Looking Statements

This press release contains certain forward-looking statements that are subject to a number of risks and uncertainties, including without limitation the risks associated with adhering to projected preclinical or clinical timelines and the uncertainties of outcomes of development work for product candidates; the potential inability to replicate preclinical data in subsequent preclinical or clinical testing; the need for substantial additional capital to fund development of product candidates beyond their initial clinical or pre-clinical stages; the risks associated with obtaining and maintaining patent protection for vaccine and antibody product candidates and the lack of patent coverage for the differential immunization platform discovery technology; and the risk of the ability to retain and recruit senior management personnel. Additional risks and uncertainties are described in IMUC's most recently filed SEC documents, such as its most recent annual report on Form 10-KSB, all quarterly reports on Form 10-Q and any current reports on Form 8-K. IMUC undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

###